Olorofim (F901318) is an experimental antifungal drug being developed for invasive mold infections.

[1][2] If approved it would be a first-in-class medication (for the orotomide class).

In 2023, the FDA decided not to approve the drug and to request more data about the safety of the drug.

[3] Olorofim does not inhibit growth of Candida species.

[2]